Clonomab
First Denosumab biosimilar in Argentina. It is an antiresorptive agent indicated for the management of metastatic bone disease in patients with solid tumors or multiple myeloma, and for the treatment of giant cell tumor of bone and hypercalcemia of malignancy.
Therapeutic Area
Other agents modifying bone structure and mineralization. Antiresorptive agent for oncology use.
Active Ingredient
Denosumab
Line
Hematology + Oncology
Dosage forms
Vial containing 120mg of Denosumab in 1.7mL of solution for injection. (70mg/mL) .
Subcutaneous administration
